FAIR VALUE MEASUREMENTS - Narrative (Details) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
|
Dec. 31, 2024
USD ($)
|
Dec. 31, 2023
USD ($)
|
Dec. 31, 2022
USD ($)
|
|
| Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis | |||
| Impairment of goodwill | $ 36,264 | $ 0 | $ 52,071 |
| Impairment of indefinite-lived intangible assets | $ 8,545 | $ 0 | $ 40,240 |
| Contingent Consideration | RockyMounts | |||
| Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis | |||
| Discount rate | 0.13 | ||
| Contingent Consideration | TRED | |||
| Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis | |||
| Discount rate | 0.115 | ||
| X | ||||||||||
- Definition Value of input used to measure contingent consideration liability from business combination. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|